Monitoring and predicting the fine balance between efficient immune activation and immunotoxicity in the context of CAR-T Cell Therapy demands accurate methods of biomarker measurements. Our ultra-sensitive Simoa technologies enable healthy baseline quantification of cytokines, and therefore recognition of sub-inflammation and also the early elevation of cytokine profiles.

Learn more about how Simoa ultra-sensitive biomarker detection platforms can monitor cytokine release in addition to neurotoxicity with the goal of successful and safe cell therapy in this interactive document.

Request More Information